Skyhawk Therapeutics Announces Positive Interim Phase 1 Results for SKY-0515 in Huntington's Disease

Skyhawk Therapeutics announced positive interim results from its Phase 1 clinical trial of SKY-0515 for Huntington's disease (HD). The trial showed do...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricing
One Research Court, Suite 450, Rockville, MD 20850
info@pienomial.com
+91 9876543210
© 2025 Pienomial. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/Skyhawk Therapeutics Announces Positive Interim Phase 1 Results for SKY-0515 in Huntington's Disease